Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials

Purpose. The aim of this study was to directly compare the efficacy and the safety of the two agents for postmenopausal women. Methods/Principal Findings. Electronic databases were searched for relevant articles that met our predefined inclusion criteria. Seven randomized controlled trials (RCTs) in...

Full description

Saved in:
Bibliographic Details
Main Authors: Tiao Lin, Shi-Gui Yan, Xun-Zi Cai, Zhi-Min Ying, Fu-Zhen Yuan, Xi Zuo
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2014/796510
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552647570227200
author Tiao Lin
Shi-Gui Yan
Xun-Zi Cai
Zhi-Min Ying
Fu-Zhen Yuan
Xi Zuo
author_facet Tiao Lin
Shi-Gui Yan
Xun-Zi Cai
Zhi-Min Ying
Fu-Zhen Yuan
Xi Zuo
author_sort Tiao Lin
collection DOAJ
description Purpose. The aim of this study was to directly compare the efficacy and the safety of the two agents for postmenopausal women. Methods/Principal Findings. Electronic databases were searched for relevant articles that met our predefined inclusion criteria. Seven randomized controlled trials (RCTs) involving 4054 women were identified and included. Although Aln was more effective than Rlx in increasing bone mineral density (BMD), no statistical differences were observed in reducing the risk of neither vertebral fractures (P=0.45) nor nonvertebral fractures (P=0.87) up to two-year followup. Aln reduced the risk of vasomotor (P=0.006) but increased the risk of diarrhea compared to Rlx (P=0.01). Our subgroup analysis further indicated the difference between Aln and Rlx in fracture risk and was not materially altered by the administration pattern, the age. The weekly strategy of Aln would further reduce the upper gastrointestinal (GI) disorders and might gain more bone mass increment at lumbar spine compared to its daily treatment. Conclusion. There was no evidence of difference of fracture risk reduction between Aln and Rlx. In addition, age did not obviously influence their relative antifracture efficacy. For Aln the weekly strategy would further reduce the upper GI disorders and gain more bone mass increment compared to the daily treatment. During clinical decision making, the patients’ adherence and the related side-effects associated with both drugs should also be taken into account.
format Article
id doaj-art-6c51c9386b194f9594a7c8b7814e5794
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-6c51c9386b194f9594a7c8b7814e57942025-02-03T05:58:13ZengWileyInternational Journal of Endocrinology1687-83371687-83452014-01-01201410.1155/2014/796510796510Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled TrialsTiao Lin0Shi-Gui Yan1Xun-Zi Cai2Zhi-Min Ying3Fu-Zhen Yuan4Xi Zuo5Department of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Epidemiology and Biostatistics, School of Public Health, Drexel University, Philadelphia, PA 19102, USAPurpose. The aim of this study was to directly compare the efficacy and the safety of the two agents for postmenopausal women. Methods/Principal Findings. Electronic databases were searched for relevant articles that met our predefined inclusion criteria. Seven randomized controlled trials (RCTs) involving 4054 women were identified and included. Although Aln was more effective than Rlx in increasing bone mineral density (BMD), no statistical differences were observed in reducing the risk of neither vertebral fractures (P=0.45) nor nonvertebral fractures (P=0.87) up to two-year followup. Aln reduced the risk of vasomotor (P=0.006) but increased the risk of diarrhea compared to Rlx (P=0.01). Our subgroup analysis further indicated the difference between Aln and Rlx in fracture risk and was not materially altered by the administration pattern, the age. The weekly strategy of Aln would further reduce the upper gastrointestinal (GI) disorders and might gain more bone mass increment at lumbar spine compared to its daily treatment. Conclusion. There was no evidence of difference of fracture risk reduction between Aln and Rlx. In addition, age did not obviously influence their relative antifracture efficacy. For Aln the weekly strategy would further reduce the upper GI disorders and gain more bone mass increment compared to the daily treatment. During clinical decision making, the patients’ adherence and the related side-effects associated with both drugs should also be taken into account.http://dx.doi.org/10.1155/2014/796510
spellingShingle Tiao Lin
Shi-Gui Yan
Xun-Zi Cai
Zhi-Min Ying
Fu-Zhen Yuan
Xi Zuo
Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
International Journal of Endocrinology
title Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
title_full Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
title_fullStr Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
title_full_unstemmed Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
title_short Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
title_sort alendronate versus raloxifene for postmenopausal women a meta analysis of seven head to head randomized controlled trials
url http://dx.doi.org/10.1155/2014/796510
work_keys_str_mv AT tiaolin alendronateversusraloxifeneforpostmenopausalwomenametaanalysisofsevenheadtoheadrandomizedcontrolledtrials
AT shiguiyan alendronateversusraloxifeneforpostmenopausalwomenametaanalysisofsevenheadtoheadrandomizedcontrolledtrials
AT xunzicai alendronateversusraloxifeneforpostmenopausalwomenametaanalysisofsevenheadtoheadrandomizedcontrolledtrials
AT zhiminying alendronateversusraloxifeneforpostmenopausalwomenametaanalysisofsevenheadtoheadrandomizedcontrolledtrials
AT fuzhenyuan alendronateversusraloxifeneforpostmenopausalwomenametaanalysisofsevenheadtoheadrandomizedcontrolledtrials
AT xizuo alendronateversusraloxifeneforpostmenopausalwomenametaanalysisofsevenheadtoheadrandomizedcontrolledtrials